Intarcia Therapeutics Inc. will work with biopharmaceutical services business Quintiles Transnational Corp. on a once-a-year treatment for Type 2 diabetes.
Durham, N.C.-based Quintiles has 14 facilities in the United States where it helps companies with clinical testing and other aspects of the pharmaceutical business.
Hayward-based Intarcia didn’t say what it will pay Quintiles for its help.
The two will work on ITCA 650, a matchstick sized pump that is implanted under a patient’s skin to deliver a drug for a whole year. It’s aimed at Type 2 diabetes and is about to start Phase III testing.
No comments:
Post a Comment